Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma

作     者：Dong-Qin Xia Yong Zhou Shuang Yang Fang-Fei Li Li-Ya Tian Yan-Hua Li Hai-Yan Xu Cai-Zhi Xiao Wei Wang 

作者机构：Oncology Treatment Center of Traditional Chinese MedicineChongqing University Cancer HospitalChongqing 400030China Department of OncologyChongqing Weisiteng Biotech Translational Research InstituteChongqing 430039China Chongqing Key Laboratory on Big Data for Bio IntelligenceChongqing University of Posts and TelecommunicationsChongqing 430065China 

出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文版）（电子版）)

年 卷 期：2024年第16卷第3期

页      面：798-809页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Natural Science Foundation of Chongqing,China,No.cstc2021jcyj-msxmX0501 Chongqing Medical Scientific Research Project(Joint Project of Chongqing Health Commission and Science and Technology Bureau),No.2022QNXM074 

主　　题：Pancreatic ductal adenocarcinoma Carbohydrate antigen 19-9 Tumor size Pathologic response Biomarkers 

摘      要：BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a common cancer with increasing morbidity and mortality due to changes of social *** To evaluate the significance of serum carbohydrate antigen 19-9(CA19-9)and tumor size changes pre-and post-neoadjuvant therapy(NAT).METHODS This retrospective study was conducted at the Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment,Chongqing University Cancer *** study specifically assessed CA19-9 levels and tumor size before and after *** A total of 156 patients who completed NAT and subsequently underwent tumor resection were included in this *** average age was 65.4±10.6 years and 72(46.2%)patients were *** survival analysis,we defined the post-NAT serum CA19-9 level/pre-NAT serum CA19-9 level as the CA19-9 ratio(CR).The patients were divided into three groups:CR0.5 and*** regard to tumor size measured by both computed tomography and magnetic resonance imaging,we defined the post-NAT tumor size/pre-NAT tumor size as the tumor size ratio(TR).The patients were then divided into three groups:TR0.5 and*** on these groups divided according to CR and TR,we performed both overall survival(OS)and disease-free survival(DFS)***-rank tests showed that both OS and DFS were significantly different among the groups according to CR and TR(P0.05).CR and TR after NAT were associated with increased odds of achieving a complete or near-complete pathologic ***,CR(hazard ratio:1.721,95%CI:1.373-3.762;P=0.006),and TR(hazard ratio:1.435,95%CI:1.275-4.363;P=0.014)were identified as independent factors associated with *** This study demonstrated that post-NAT serum CA19-9 level/pre-NAT serum CA19-9 level and post-NAT tumor size/pre-NAT tumor size were independent factors associated with OS in patients with PDAC who received NAT and subsequent surgical resection.